SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐17 inhibitor

Balestri, Riccardo; Rech, Giulia; Cr, Girardelli

doi:10.1111/jdv.16571

Cited by 37 publications

(36 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 To date, more and more data regarding the risk of COVID-19 infection in patients receiving SBT become available. [2][3][4][5] To enrich these data, we evaluated the frequency of severe COVID-19 infections, defined as hospitalization or death, in psoriasis patients receiving SBT, especially during the 4 months following SBT initiation.…”

Section: Systemic or Biologic Treatment In Psoriasis Patients Does Nomentioning

confidence: 99%

“…2 Moreover, biologic treatment using immunosuppressive drugs such as guselkumab, ustekinumab, adalimumab, secukinumab, brodalumab or ixekizumab may even protect against the onset and evolution of COVID-19 infection. 3,4,7 [Correction added on 28 August 2020, after first online publication: On paragraph 8, the word 'brodalumab' has been added in this version. ]…”

Section: Systemic or Biologic Treatment In Psoriasis Patients Does Nomentioning

confidence: 99%

See 1 more Smart Citation

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19

Fougerousse

Perrussel²,

Becherel³

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Systemic or Biologic Treatment In Psoriasis Patients Does Nomentioning

confidence: 99%

Section: Systemic or Biologic Treatment In Psoriasis Patients Does Nomentioning

confidence: 99%

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19

Fougerousse

Perrussel²,

Becherel³

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…However, there is an optimistic report that all patients with psoriasis on biologic therapies who were hospitalized because of COVID‐19 infection survived and recovered from infection 26 . There are case reports on successful recovery from COVID‐19 of patients that for different reasons did not pause treatment with biologics 27,28 and an anecdotical report on improvement of the respiratory condition, normalization of body temperature and progressive relief of myalgia and fatigue symptoms after self‐administered injection of guselkumab by a psoriatic patient 29 …”

Section: Introductionmentioning

confidence: 99%

Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic

Chernyshov

Tómas-Aragonés

Augustin

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

The pandemic of COVID-19 is a global challenge for health care, and dermatologists are not standing apart from trying to meet this challenge. The European Academy of Dermatology and Venereology (EADV) has collected recommendations from its Task Forces (TFs) related to COVID-19. The Journal of the EADV has established a COVID-19 Special Forum giving free access to related articles. The psychosocial effects of the pandemic, an increase in contact dermatitis and several other skin diseases because of stress, disinfectants and protective equipment use, especially in healthcare workers, the temporary limited access to dermatologic care, the dilemma whether or not to pause immunosuppressive therapy, and, finally, the occurrence of skin lesions in patients infected by COVID-19 all contribute to significant quality of life (QoL) impairment. Here, we present detailed recommendations of the EADV TF on QoL and patient-oriented outcomes on how to improve QoL in dermatologic patients during the COVID-19 pandemic for several different groups of patients and for the general population.

show abstract

“…This dual role of inflammatory mediators in the pathogenesis of COVID-19 might have important implications for the use of biologics targeting different cytokines in patients with psoriasis and other inflammatory, autoimmune, and allergic skin disorders. In this regard, although the protective or pathogenic role of the IL-23/IL-17 axis in immune responses against SARS-CoV-2 is unknown, three reports of psoriatic patients receiving anti-IL-23 and anti-IL-17 antibodies showed no increased risk of severe disease after testing positive for COVID-19 [8,10,75], and even one case showed improvement of the respiratory symptoms after the administration of Guselkumab [10]. Meanwhile, blocking type 2 cytokine axes seems not to increase the risk of SARS-CoV-2 infection, as demonstrated by several reports about the safety of dupilumab, a human monoclonal antibody against the alfa subunit of IL-4 receptor, in patients with atopic dermatitis [14,15,31].…”

Section: Implications Of Covid-19 In Dermatologymentioning

confidence: 99%

Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations

2020

View full text Add to dashboard Cite

The human infection caused by the novel SARS-CoV-2 is a public health emergency of international concern. Although the disease associated to this virus, named COVID-19, mainly affects the lungs, the infection can spread to extrapulmonary tissues, causing multiorgan involvement in severely ill patients. The broad infective capacity of SARS-CoV-2 is related to the pattern of expression of the viral entry factors ACE2 and TMPRSS2 in human tissues. As such, the respiratory and gastrointestinal tracts are at high risk for SARS-CoV-2 infection due to their high expression of ACE2 and TMPRSS2, which explains the clinical phenotype described in the vast majority of infected patients that includes pneumonia and diarrhea. Recently, preoccupation about the potential of the virus to infect the skin has been raised by dermatologists due to the increasing observations of cutaneous manifestations in patients with SARS-CoV-2 infection. Although there is little evidence of the expression of ACE2 and TMPRSS2 in the normal skin, the dermatological findings observed among COVID-19 patients warrants further investigation to delineate the mechanisms of skin affection after SARS-CoV-2 infection. Here, we provide a summary of the dermatological findings observed among patients with laboratory-confirmed SARS-CoV-2 infection based on recent reports. In addition, we analyze possible mechanisms of skin injury in COVID-19 patients and discuss about the risk of individuals with chronic skin conditions for SARS-CoV-2 infection. The present review constitutes a useful informative tool to improve our understanding of the pathophysiological mechanisms of COVID-19 and the possible implications of the current pandemic in dermatology.

show abstract

SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐17 inhibitor

Cited by 37 publications

References 5 publications

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19

Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic

Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations

Contact Info

Product

Resources

About